Peri-implantitis: zirconia as a waveguide for targeted photodynamic therapy

The management of peri-implantitis remains a major clinical challenge: bacterial colonization often progresses along the implant shaft to the intraosseous area, risking osteomyelitis and requiring invasive treatments ranging from surgical debridement to implant removal. To reduce this therapeutic burden, Photodynamic Inactivation (PDI) — using a 670 nm red laser and a methylene blue photosensitizer — offers an attractive bactericidal alternative. However, access to the deep bacterial niche at the bone-implant interface remains the primary obstacle.

This in silico study uses for the first time a Monte Carlo radiation transfer (MCRT) simulation based on computed tomography (CT) to quantify the waveguiding capabilities of zirconium dioxide (ZrO2) implants. The objective is to mathematically model light propagation through the implant towards human and porcine mandibular tissues, integrating experimentally measured optical properties (absorption, scattering, anisotropy).

The authors test the hypothesis that zirconia allows efficient light propagation beyond the bone-implant interface, reaching a power density above the critical threshold of 10 mW/cm² required for a bactericidal effect. The study also evaluates whether modifications to the implant design or the positioning of the light source allow for specific targeting of biofilm areas, while verifying the absence of major differences between human and porcine tissues to facilitate future preclinical testing.

A hybrid approach: from photography to 3D simulation

How to precisely quantify the propagation of laser light in the alveolar bone? To address this challenge, researchers have developed mathematical modeling using Monte Carlo simulation (MCRT), coupled with CT imaging of a human facial skeleton. This in silico architecture predicts the behavior of photons through the implant and surrounding tissues.

The experimental protocol integrated real physical measurements to feed the algorithm:

• Optical characterization: The team first measured the absorption, scattering, and anisotropy coefficients of zirconia (ZrO2) discs, mandibular bone fragments (human and porcine), and human gingiva.
• PDI Parameters: The simulation modeled the excitation of Methylene Blue by a red laser at 670 nm. The bactericidal efficiency threshold was set at 10 mW/cm², with a reference energy density of 15 J/cm² for the standard PDI protocol.
• Topographic optimization: An accelerated path tracing algorithm allowed for the evaluation of the impact of the implant design and the light source position on energy distribution.

The analysis focused on the ability of ZrO2 to act as a waveguide capable of delivering sufficient light power beyond the implant-bone interface, while comparing the transferability of results between human and porcine models.

Waveguiding capacity and bactericidal thresholds

Monte Carlo simulation (MCRT) demonstrates that zirconia (ZrO2) implants act as efficient waveguides, propagating 670 nm red light beyond the implant-bone interface. The power per unit area values obtained are above the minimum threshold of 10 mW/cm², ensuring sufficient intensity to induce effective photodynamic inactivation (PDI).

This light transmission achieves bactericidal levels capable of destroying the biofilm, even in deep intra-osseous areas. As a reminder, previous work cited by the authors had already established the efficacy of PDI on zirconia with energy densities of 15 J/cm².

Comparisons and design modulations

The study revealed no major differences between human and porcine mandibular tissues in terms of light propagation. This observation is crucial as it validates the relevance of future animal models for preclinical testing.

Furthermore, the topographical distribution of light energy around the implant proved to be sensitive to two key factors:

• Implant design: geometry directly influences photon trajectory and scattering.
• Source placement: allows the treated area to be adjusted according to the suspected location of the biofilm.

Analysis of the waveguiding capabilities of zirconia

The results of this Monte Carlo simulation (MCRT) confirm that zirconia (ZrO2) does not only behave as an inert material, but as a true optical waveguide. By reaching surface power density values exceeding the critical threshold of 10 mW/cm², the device delivers sufficient energy to activate methylene blue and induce a bactericidal effect through photodynamic inactivation (PDI) down to the bone-implant interface. For the clinician, this means that the biofilm colonizing the intraosseous part, usually inaccessible to non-invasive treatments, becomes a potential therapeutic target.

The study highlights, however, limitations inherent to its in silico design. Although the model integrates the real optical properties of human and porcine tissues, it is a mathematical quantification that does not take into account dynamic biological variables such as the presence of blood or crevicular fluid, which are likely to modify light absorption. Furthermore, the observed efficacy remains dependent on the specific coupling between a wavelength of 670 nm and the photosensitizer used.

Nevertheless, the consistency of data across species (human and porcine) and the correlation with previous in vitro studies — which already showed a superiority of zirconia over titanium in PDI — reinforce the validity of the model. This advancement suggests that optimizing implant design and light source positioning would allow for tailored management of peri-implantitis, thereby reducing the need for invasive debridement surgeries or explantation.

Study summary

This Monte Carlo radiation transport (MCRT) simulation demonstrates that zirconium dioxide (ZrO2) implants act as efficient waveguides for photodynamic therapy (PDI) at 670 nm. The results quantify light propagation consistently exceeding the bactericidal threshold of 10 mW/cm² beyond the implant-bone interface, allowing for the activation of methylene blue within the intraosseous biofilm, which is normally inaccessible.

In concrete terms, for the practitioner:

• Harness the translucency of zirconia: Unlike opaque titanium, ZrO2 allows for the treatment of biofilm infiltrated along the implant-bone connection without invasive surgical stripping.
• Optimize the PDI protocol: An energy density of 15 J/cm² coupled with a red laser (670 nm) is sufficient to induce the formation of reactive oxygen species (ROS) lethal to peri-implant bacteria.
• Customize targeting: The implant design and the light source position modulate the topographical distribution of the flux; adapt your illumination angle according to the specific location of the bone defects observed on the scan.

Technical lexicon of the study

Peri-implantitis (PI): A major inflammatory complication related to the formation of bacterial biofilms on implants, for which current treatment varies from local antibiotic therapy to invasive surgical extraction.

Zirconium dioxide (ZrO2): Ceramic material constituting the implant, whose optical transmission properties (waveguiding) are exploited here to treat the biofilm in depth, unlike opaque titanium.

Photodynamic Inactivation (PDI): Antimicrobial therapy using a red laser (670 nm) to excite a photosensitizer, inducing the formation of cytotoxic species to destroy the bacterial biofilm.

Monte Carlo Simulation (MCRT): Mathematical method of stochastic modeling (Monte Carlo Simulation of Radiation Transport) used to predict photon paths and quantify light power distribution within tissues.

Reactive Oxygen Species (ROS): Cytotoxic molecules generated during PDI that damage bacterial cell walls, causing cell death and biofilm disintegration.

Waveguiding: Specific capacity of ZrO2 to propagate light beyond the direct illumination zone, allowing it to reach infected sites at the implant-bone interface.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.